Leerink Partnrs Increases Earnings Estimates for Bio-Techne

Key Points

• Leerink Partners has updated Bio-Techne's Q4 2026 earnings per share (EPS) estimate to $0.51, slightly higher than the previous estimate of $0.50.
• Bio-Techne reported $0.53 EPS for its last quarter, beating analysts' expectations of $0.50, and showed a 3.6% revenue increase year-over-year.
• Multiple firms, including Citigroup and Stephens, have upgraded Bio-Techne's ratings, with price targets now ranging up to $70.00.

Bio-Techne Corp (NASDAQ:TECH - Free Report) - Equities research analysts at Leerink Partnrs increased their Q4 2026 earnings per share (EPS) estimates for shares of Bio-Techne in a research note issued on Monday, October 13th. Leerink Partnrs analyst P. Souda now anticipates that the biotechnology company will post earnings per share of $0.51 for the quarter, up from their previous estimate of $0.50. The consensus estimate for Bio-Techne's current full-year earnings is $1.67 per share. Leerink Partnrs also issued estimates for Bio-Techne's Q2 2027 earnings at $0.46 EPS.

Bio-Techne (NASDAQ:TECH - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $0.53 earnings per share for the quarter, topping analysts' consensus estimates of $0.50 by $0.03. The company had revenue of $316.96 million during the quarter, compared to analysts' expectations of $315.14 million. Bio-Techne had a return on equity of 13.43% and a net margin of 6.02%.The business's revenue for the quarter was up 3.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.49 earnings per share.

TECH has been the topic of a number of other reports. Citigroup upgraded Bio-Techne from a "neutral" rating to a "buy" rating and increased their price target for the stock from $55.00 to $70.00 in a research report on Thursday, August 21st. Stephens upgraded Bio-Techne to a "strong-buy" rating and set a $65.00 price objective for the company in a report on Tuesday, July 22nd. Royal Bank Of Canada raised Bio-Techne from a "hold" rating to a "moderate buy" rating in a research report on Wednesday, September 3rd. TD Cowen lifted their price objective on Bio-Techne from $65.00 to $70.00 and gave the company a "buy" rating in a report on Tuesday. Finally, Cowen restated a "buy" rating on shares of Bio-Techne in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $70.58.

Bio-Techne Price Performance

Shares of NASDAQ TECH opened at $59.58 on Thursday. The company has a market capitalization of $9.28 billion, a price-to-earnings ratio of 129.52, a PEG ratio of 3.78 and a beta of 1.48. Bio-Techne has a 1-year low of $46.01 and a 1-year high of $80.80. The company has a debt-to-equity ratio of 0.18, a current ratio of 3.46 and a quick ratio of 2.38. The business has a 50-day moving average of $54.85 and a 200-day moving average of $52.56.

Institutional Trading of Bio-Techne

A number of institutional investors have recently modified their holdings of TECH. Select Equity Group L.P. grew its holdings in shares of Bio-Techne by 129.8% during the 1st quarter. Select Equity Group L.P. now owns 5,366,003 shares of the biotechnology company's stock valued at $314,609,000 after purchasing an additional 3,030,644 shares during the last quarter. Norges Bank purchased a new position in shares of Bio-Techne during the second quarter valued at approximately $98,238,000. RGM Capital LLC bought a new stake in Bio-Techne during the first quarter valued at approximately $59,267,000. Price T Rowe Associates Inc. MD boosted its position in shares of Bio-Techne by 6.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 11,375,279 shares of the biotechnology company's stock worth $666,933,000 after purchasing an additional 721,012 shares during the period. Finally, Westfield Capital Management Co. LP bought a new position in shares of Bio-Techne in the first quarter worth approximately $39,658,000. 98.95% of the stock is currently owned by hedge funds and other institutional investors.

Bio-Techne Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, August 29th. Shareholders of record on Monday, August 18th were given a $0.08 dividend. This represents a $0.32 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend was Monday, August 18th. Bio-Techne's dividend payout ratio is presently 69.57%.

About Bio-Techne

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.